Medivir’s business focus in pharmaceutical development is in infectious diseases, which is where the majority of its projects are. The project portfolio also has some projects addressing other indications where polymerase and protease play a key role in the course of the disease. Medivir is in a range of collaborations in clinical and preclinical phases with established pharmaceutical companies and smaller biotech enterprises. Currently, our biggest focus in infectious diseases is in hepatitis C where we have two projects run with partners and two that are being developed in-house. These projects address the hepatitis C virus from two different mechanisms; inhibiting the enzymes protease and polymerase. We are currently well-positioned in the hepatitis C segment where our most advanced project, simeprevir (TMC435), which is run in partnership with Janssen Pharmaceuticals, is in global phase III registration trials.